A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors.

Autor: Juric D; Termeer Center for Targeted Therapies, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA., Barve M; Medical Oncology, Mary Crowley Cancer Research, Dallas, Texas, USA., Vaishampayan U; Internal Medicine/Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA., Roda D; Department of Medical Oncology, University Hospital, Valencia, Spain., Calvo A; Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain., Jañez NM; Department of Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain., Trigo J; Medical Oncology, Hospital Universitario Virgen de la Victoria, Málaga, Spain., Greystoke A; Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK., Harvey RD; Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA., Olszanski AJ; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA., Opyrchal M; Division of Oncology, Washington University School of Medicine in St Louis, St Louis, Missouri, USA., Spira A; Medical Oncology, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.; Medical Oncology, Virginia Cancer Specialists, US Oncology Research, NEXT Oncology Virginia, Leesburg, Virginia, USA., Thistlethwaite F; Medical Oncology, The Christie NHS Foundation Trust and University of Manchester, Manchester, UK., Jiménez B; Medical Oncology, Hospital Universitario Virgen de la Victoria, Málaga, Spain., Sappal JH; Precision and Translational Medicine, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA., Kannan K; Oncology Therapeutic Area Unit, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA., Riley J; Gastroenterology, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA., Li C; Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA., Li C; Statistical and Quantitative Sciences, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA., Gregory RC; Precision and Translational Medicine, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA., Miao H; Clinical Development, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA., Wang S; Takeda Oncology Clinical Science, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA.

Publikováno v: Cancer medicine [Cancer Med] 2024 Mar; Vol. 13 (5).